MX2019004345A - Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida. - Google Patents
Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida.Info
- Publication number
- MX2019004345A MX2019004345A MX2019004345A MX2019004345A MX2019004345A MX 2019004345 A MX2019004345 A MX 2019004345A MX 2019004345 A MX2019004345 A MX 2019004345A MX 2019004345 A MX2019004345 A MX 2019004345A MX 2019004345 A MX2019004345 A MX 2019004345A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- hydroxycyclohexylamino
- benzothiazol
- yloxy
- methylpicolinamide
- Prior art date
Links
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1r,2r)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 title 1
- IHWOVMRZEIHNGY-SATBOSKTSA-N 4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide hydrochloride Chemical class Cl.O[C@H]1[C@@H](CCCC1)NC=1SC2=C(N1)C=CC(=C2)OC2=CC(=NC=C2)C(=O)NC IHWOVMRZEIHNGY-SATBOSKTSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Esta solicitud se refiere a diversas formas cristalinas de sales de clorhidrato de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiaz ol-6-iloxi)-N-metilpicolinamida, al igual que a composiciones y métodos para su uso. En algunas formas de realización, las formas cristalinas además contienen agua ("hidratos"). Estos materiales son útiles en el tratamiento de diversas enfermedades, que incluyen glioblastoma multiforme, cáncer de mama, cáncer de páncreas y otros tumores sólidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408358P | 2016-10-14 | 2016-10-14 | |
| PCT/IB2017/056379 WO2018069892A1 (en) | 2016-10-14 | 2017-10-13 | Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004345A true MX2019004345A (es) | 2019-07-01 |
Family
ID=60320932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004345A MX2019004345A (es) | 2016-10-14 | 2017-10-13 | Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10934273B2 (es) |
| EP (1) | EP3526217B1 (es) |
| JP (1) | JP7068288B2 (es) |
| KR (1) | KR20190064589A (es) |
| CN (1) | CN109843880B (es) |
| AU (1) | AU2017342239B2 (es) |
| BR (1) | BR112019006914A2 (es) |
| CA (1) | CA3039764A1 (es) |
| CL (1) | CL2019001008A1 (es) |
| ES (1) | ES2949414T3 (es) |
| IL (1) | IL265893A (es) |
| MX (1) | MX2019004345A (es) |
| RU (1) | RU2019114208A (es) |
| WO (1) | WO2018069892A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
| CA3162315A1 (en) * | 2019-12-20 | 2021-06-24 | Marinus Jacobus Verwijs | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101432281B (zh) * | 2006-04-19 | 2013-08-28 | 诺瓦提斯公司 | 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法 |
| AU2007237904B2 (en) * | 2006-04-19 | 2011-03-03 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
| PT2704713T (pt) * | 2011-05-05 | 2017-04-24 | Novartis Ag | Inibidores de csf-1r para tratamento de tumores cerebrais |
| EP3233918A1 (en) * | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
-
2017
- 2017-10-13 RU RU2019114208A patent/RU2019114208A/ru not_active Application Discontinuation
- 2017-10-13 EP EP17797745.1A patent/EP3526217B1/en active Active
- 2017-10-13 CA CA3039764A patent/CA3039764A1/en not_active Abandoned
- 2017-10-13 WO PCT/IB2017/056379 patent/WO2018069892A1/en not_active Ceased
- 2017-10-13 BR BR112019006914A patent/BR112019006914A2/pt not_active IP Right Cessation
- 2017-10-13 AU AU2017342239A patent/AU2017342239B2/en not_active Ceased
- 2017-10-13 ES ES17797745T patent/ES2949414T3/es active Active
- 2017-10-13 CN CN201780063254.XA patent/CN109843880B/zh active Active
- 2017-10-13 JP JP2019520040A patent/JP7068288B2/ja not_active Expired - Fee Related
- 2017-10-13 US US16/341,124 patent/US10934273B2/en active Active
- 2017-10-13 KR KR1020197010527A patent/KR20190064589A/ko not_active Ceased
- 2017-10-13 MX MX2019004345A patent/MX2019004345A/es unknown
-
2019
- 2019-04-07 IL IL265893A patent/IL265893A/en unknown
- 2019-04-12 CL CL2019001008A patent/CL2019001008A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3526217B1 (en) | 2023-04-19 |
| IL265893A (en) | 2019-06-30 |
| EP3526217A1 (en) | 2019-08-21 |
| JP7068288B2 (ja) | 2022-05-16 |
| AU2017342239B2 (en) | 2020-05-28 |
| ES2949414T3 (es) | 2023-09-28 |
| WO2018069892A1 (en) | 2018-04-19 |
| RU2019114208A3 (es) | 2020-11-18 |
| US10934273B2 (en) | 2021-03-02 |
| CA3039764A1 (en) | 2018-04-19 |
| KR20190064589A (ko) | 2019-06-10 |
| US20200190057A1 (en) | 2020-06-18 |
| AU2017342239A1 (en) | 2019-04-18 |
| BR112019006914A2 (pt) | 2019-07-02 |
| RU2019114208A (ru) | 2020-11-16 |
| CN109843880B (zh) | 2023-12-01 |
| CL2019001008A1 (es) | 2019-06-21 |
| CN109843880A (zh) | 2019-06-04 |
| JP2019530719A (ja) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519401020B1 (ar) | مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2 | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| EA201790376A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201692513A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| PH12019501350B1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| EA201891526A2 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| PH12018501084B1 (en) | Heterocyclic compounds as immunomodulators | |
| MX2015013481A (es) | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. | |
| PH12015501868A1 (en) | Inhibitors of histone demethylases | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| PH12019501896A1 (en) | Therapeutic dendrimers | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
| EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| MX390051B (es) | Antagonistas de ep4. | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2019004345A (es) | Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida. | |
| EA201892311A1 (ru) | Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга | |
| EA202190045A1 (ru) | Составы/композиции, содержащие ибрутиниб | |
| PH12017501134A1 (en) | Fumagillol derivatives | |
| PE20170522A1 (es) | Forma polimorfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzheimer | |
| EA201990556A1 (ru) | Ингибиторы клеточных метаболических процессов |